J. Harris

Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL.

Confluent Surgical, Inc. designed and developed medical devices. The company was founded by Farhad Khosravi in August 1998 and was headquartered in Waltham, MA.

The Royal Swedish Academy of Sciences provides research and development services on sciences. The non-profit company is based in Stockholm, Sweden.

Part of Nektar Therapeutics, Shearwater Corp. is a company that provides research services focused on health care applications of advanced PEGylation. The company is based in Huntsville, AL. The company was founded by James R. Hudson, J. Milton Harris. Shearwater was acquired by Nektar Therapeutics on July 02, 2001 for $164.50 million.

Serina Therapeutics, Inc. is a pharmaceutical company, which engages in the development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley in 2006 and is headquartered in Huntsville, AL.

The HudsonAlpha Institute for Biotechnology is a non-profit organization. It focuses on conducting genomics-based research to improve human health and well being; implementing genomic medicine, sparking economic development; and providing educational outreach to nurture the next generation of biotech researchers and entrepreneurs, as well as to create a biotech literate public. The company was founded by James R. Hudson, Jr. and Lonnie S. McMillian in 2008 and is headquartered in Huntsville, AL.

Canaria Therapeutics, Inc. operates as a biotechnology company. The company was founded in 2018 and is headquartered in Huntsville, AL.